{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:16:45Z","timestamp":1793863005612,"version":"4.6.1"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020703","name":"Department of Pharmaceutical Sciences, St. John's University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020703","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023983","name":"Babasaheb Bhimrao Ambedkar University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023983","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jaut.2025.103425","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T17:11:37Z","timestamp":1745946697000},"page":"103425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["VEXAS syndrome: A newly identified X-Linked hematoinflammatory disorder \u2013 A comprehensive overview of its genetic, molecular, inflammatory, and clinical landscape"],"prefix":"10.1016","volume":"154","author":[{"given":"Alpana","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8440-5467","authenticated-orcid":false,"given":"Rishabh","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.jaut.2025.103425_bib1","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jaut.2025.103425_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41584-020-00559-x","article-title":"Somatic mutations cause VEXAS syndrome","volume":"17","author":"Onuora","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"issue":"10","key":"10.1016\/j.jaut.2025.103425_bib3","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/art.41743","article-title":"Somatic mutations in UBA1 define a distinct subset of relapsing polychondritis patients with VEXAS","volume":"73","author":"Ferrada","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2025.103425_bib4","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.7326\/L21-0023","article-title":"Severe joint involvement in VEXAS syndrome: a case report","volume":"174","author":"Lacombe","year":"2021","journal-title":"Ann. Intern. Med. U. S."},{"key":"10.1016\/j.jaut.2025.103425_bib5","first-page":"6","volume":"vol. 11","author":"Lacombe","year":"2022"},{"issue":"4","key":"10.1016\/j.jaut.2025.103425_bib6","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.jaad.2022.10.052","article-title":"Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: a multicenter retrospective study of 59 cases","volume":"88","author":"Zakine","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.jaut.2025.103425_bib7","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1080\/01676830.2022.2126501","article-title":"Recurrent orbital inflammation associated with VEXAS syndrome","volume":"43","author":"Beecher","year":"2024","journal-title":"Orbit"},{"key":"10.1016\/j.jaut.2025.103425_bib8","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1111\/jth.15858","article-title":"Systematic search for the UBA1 mutation in men after a first episode of venous thromboembolism: a monocentric study","volume":"20","author":"Khider","year":"2022","journal-title":"J. Thromb. Hemost."},{"issue":"3","key":"10.1016\/j.jaut.2025.103425_bib9","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1001\/jamaoto.2021.4092","article-title":"Ear, nose, throat, and bronchial involvements in VEXAS syndrome: specifying the spectrum of clinical features","volume":"148","author":"Beaumesnil","year":"2022","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"issue":"4","key":"10.1016\/j.jaut.2025.103425_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2024.105700","article-title":"VEXAS syndrome: an update","volume":"91","author":"Khitri","year":"2024","journal-title":"Jt. Bone Spine"},{"issue":"3","key":"10.1016\/j.jaut.2025.103425_bib11","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/bjd.20805","article-title":"Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients","volume":"186","author":"Georgin-Lavialle","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"8","key":"10.1016\/j.jaut.2025.103425_bib12","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood.2022016642","article-title":"Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study","volume":"140","author":"Heiblig","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jaut.2025.103425_bib13","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bjh.17893","article-title":"Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry","volume":"196","author":"Comont","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.jaut.2025.103425_bib14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/ajh.27156","article-title":"VEXAS syndrome: clinical, hematologic features and a practical approach to diagnosis and management","volume":"99","author":"Koster","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.jaut.2025.103425_bib15","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1016\/j.mayocp.2021.06.006","article-title":"Clinical heterogeneity of the VEXAS syndrome: a case series","volume":"96","author":"Koster","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.jaut.2025.103425_bib16","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaci.2021.05.014","article-title":"Adult-onset autoinflammation caused by somatic mutations in UBA1: a Dutch case series of patients with VEXAS","volume":"149","author":"van der Made","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.jaut.2025.103425_bib17","doi-asserted-by":"crossref","first-page":"E99","DOI":"10.1093\/rheumatology\/kead506","article-title":"Challenging the paradigm: a case of early-onset VEXAS syndrome","volume":"63","author":"S\u00e1nchez-Hern\u00e1ndez","year":"2024","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.jaut.2025.103425_bib18","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/annrheumdis-2021-220089","article-title":"Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis","volume":"80","author":"Tsuchida","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.jaut.2025.103425_bib19","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jama.2022.24836","article-title":"Estimated prevalence and clinical manifestations of UBA1 variants associated with VEXAS syndrome in a clinical population","volume":"329","author":"Beck","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jaut.2025.103425_bib20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1128\/mr.54.3.266-292.1990","article-title":"The fungal vacuole: composition, function, and biogenesis","volume":"54","author":"Klionsky","year":"1990","journal-title":"Microbiol. Rev."},{"issue":"4","key":"10.1016\/j.jaut.2025.103425_bib21","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1105\/tpc.11.4.587","article-title":"Plant vacuoles","volume":"11","author":"Marty","year":"1999","journal-title":"Plant Cell"},{"issue":"34","key":"10.1016\/j.jaut.2025.103425_bib22","doi-asserted-by":"crossref","first-page":"55863","DOI":"10.18632\/oncotarget.10150","article-title":"Cytoplasmic vacuolization in cell death and survival","volume":"7","author":"Shubin","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.jaut.2025.103425_bib23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10565-012-9212-3","article-title":"Cytoplasmic vacuolization during exposure to drugs and other substances","volume":"28","author":"Aki","year":"2012","journal-title":"Cell Biol. Toxicol."},{"issue":"26","key":"10.1016\/j.jaut.2025.103425_bib24","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1182\/blood.2021010811","article-title":"Vacuolization of hematopoietic precursors: an enigma with multiple etiologies","volume":"137","author":"Gurnari","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jaut.2025.103425_bib25","first-page":"487","article-title":"Alcohol-induced vacuolization in bone marrow cells: ultrastructure and mechanism of formation","volume":"13","author":"Yeung","year":"1988","journal-title":"Blood Cells (N. Y.)"},{"issue":"1","key":"10.1016\/j.jaut.2025.103425_bib26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/MOH.0b013e32834da9d2","article-title":"Update on anemia and neutropenia in copper deficiency","volume":"19","author":"Lazarchick","year":"2012","journal-title":"Curr. Opin. Hematol."},{"issue":"4","key":"10.1016\/j.jaut.2025.103425_bib27","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1182\/blood-2002-01-0256","article-title":"Copper deficiency masquerading as myelodysplastic syndrome","volume":"100","author":"Gregg","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jaut.2025.103425_bib28","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3324\/haematol.12121","article-title":"Hypocupremia and bone marrow failure","volume":"93","author":"Haddad","year":"2008","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jaut.2025.103425_bib29","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/leu.2008.389","article-title":"Erythroid precursors from patients with low-risk myelodysplasia demonstrate ultrastructural features of enhanced autophagy of mitochondria","volume":"23","author":"Houwerzijl","year":"2009","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.jaut.2025.103425_bib30","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1093\/rheumatology\/kead245","article-title":"Targeted testing of bone marrow specimens with cytoplasmic vacuolization to identify previously undiagnosed cases of VEXAS syndrome","volume":"62","author":"Hines","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2025.103425_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lfs.2018.01.010","article-title":"Spirulina ameliorates methotrexate hepatotoxicity via antioxidant, immune stimulation, and proinflammatory cytokines and apoptotic proteins modulation","volume":"196","author":"Khafaga","year":"2018","journal-title":"Life Sci"},{"issue":"9","key":"10.1016\/j.jaut.2025.103425_bib32","article-title":"Overview of methotrexate toxicity: a comprehensive literature review","volume":"14","author":"Hamed","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.jaut.2025.103425_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-224722","article-title":"Severe bone marrow suppression due to methotrexate toxicity following aceclofenac-induced acute kidney injury","volume":"2018","author":"Manappallil","year":"2018","journal-title":"BMJ Case Rep."},{"issue":"2","key":"10.1016\/j.jaut.2025.103425_bib34","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000828","article-title":"Quantitative assessment of vacuolization of myeloid precursors in VEXAS syndrome","volume":"7","author":"Rabut","year":"2023","journal-title":"HemaSphere"},{"issue":"26","key":"10.1016\/j.jaut.2025.103425_bib35","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1182\/blood.2020010177","article-title":"Therapeutic options in VEXAS syndrome: insights from a retrospective series","volume":"137","author":"Bourbon","year":"2021","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jaut.2025.103425_bib36","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1182\/blood.2021010714","article-title":"VEXAS: a vivid new syndrome associated with vacuoles in various hematopoietic cells","volume":"137","author":"Lytle","year":"2021","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jaut.2025.103425_bib37","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood.2020010286","article-title":"Novel somatic mutations in UBA1 as a cause of VEXAS syndrome","volume":"137","author":"Poulter","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2025.103425_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1466720","article-title":"Expanding the VEXAS diagnostic workup: the role of peripheral blood cytological analysis","volume":"15","author":"Baggio","year":"2024","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.jaut.2025.103425_bib39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1055\/s-0043-1770958","article-title":"VEXAS syndrome\u2014review","volume":"10","author":"Zhang","year":"2023","journal-title":"Glob Med Genet"},{"issue":"2","key":"10.1016\/j.jaut.2025.103425_bib40","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/S2352-3026(23)00375-7","article-title":"Vacuoles in bone marrow progenitors: VEXAS syndrome and beyond","volume":"11","author":"Lacombe","year":"2024","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.jaut.2025.103425_bib41","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/art.42471","article-title":"Novel somatic UBA1 variant in a patient with VEXAS syndrome","volume":"75","author":"Stiburkova","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2025.103425_bib42","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/bjh.17679","article-title":"Vacuoles in neutrophil precursors in VEXAS syndrome: diagnostic performances and threshold","volume":"195","author":"Lacombe","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"16","key":"10.1016\/j.jaut.2025.103425_bib43","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1182\/bloodadvances.2021004976","article-title":"Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1","volume":"5","author":"Obiorah","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaut.2025.103425_bib44","doi-asserted-by":"crossref","first-page":"E435","DOI":"10.1093\/rheumatology\/keab524","article-title":"Atypical splice-site mutations causing VEXAS syndrome","volume":"60","author":"Templ\u00e9","year":"2021","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.jaut.2025.103425_bib45","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000868","article-title":"Recurrent mutations of the active adenylation domain of UBA1 in atypical form of VEXAS syndrome","volume":"7","author":"Faurel","year":"2023","journal-title":"HemaSphere"},{"issue":"13","key":"10.1016\/j.jaut.2025.103425_bib46","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1182\/blood.2022016985","article-title":"Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis","volume":"140","author":"Ferrada","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jaut.2025.103425_bib47","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.chest.2022.10.011","article-title":"Pleuropulmonary manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome","volume":"163","author":"Borie","year":"2023","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.jaut.2025.103425_bib48","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/bjh.17381","article-title":"Characteristic vacuolisation of granulocytic and erythroid precursors associated with VEXAS syndrome","volume":"194","author":"Rieu","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jaut.2025.103425_bib49","article-title":"The ubiquitination machinery of the ubiquitin system","volume":"12","author":"Callis","year":"2014","journal-title":"Arab B"},{"issue":"1","key":"10.1016\/j.jaut.2025.103425_bib50","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/s41467-017-00528-1","article-title":"Genetic and epigenetic features direct differential efficiency of Xist-mediated silencing at X-chromosomal and autosomal locations","volume":"8","author":"Loda","year":"2017","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.jaut.2025.103425_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000131","article-title":"E1 ubiquitin-activating enzyme UBA-1 plays multiple roles throughout C. elegans development","volume":"4","author":"Kulkarni","year":"2008","journal-title":"PLoS Genet."},{"issue":"1","key":"10.1016\/j.jaut.2025.103425_bib52","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1038\/s41467-019-13266-3","article-title":"Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network","volume":"10","author":"Haupt","year":"2019","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.jaut.2025.103425_bib53","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.molmed.2015.08.003","article-title":"UBA1: at the crossroads of ubiquitin homeostasis and neurodegeneration","volume":"21","author":"Groen","year":"2015","journal-title":"Trends Mol. Med."},{"issue":"47","key":"10.1016\/j.jaut.2025.103425_bib54","doi-asserted-by":"crossref","first-page":"18337","DOI":"10.1074\/jbc.RA118.003975","article-title":"Crystal structure of a human ubiquitin E1\u2013 ubiquitin complex reveals conserved functional elements essential for activity","volume":"293","author":"Lv","year":"2018","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.jaut.2025.103425_bib55","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/1744666X.2023.2157262","article-title":"An update on VEXAS syndrome","volume":"19","author":"Al-Hakim","year":"2023","journal-title":"Expet Rev. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.jaut.2025.103425_bib56","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/mrcr\/rxab021","article-title":"UBA1 and DNMT3A mutations in VEXAS syndrome. A case report and literature review","volume":"6","author":"Shaukat","year":"2022","journal-title":"Mod Rheumatol Case Reports"},{"issue":"4","key":"10.1016\/j.jaut.2025.103425_bib57","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00281-015-0496-2","article-title":"Protein misfolding and dysregulated protein homeostasis in autoinflammatory diseases and beyond","volume":"37","author":"Agyemang","year":"2015","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.jaut.2025.103425_bib58","first-page":"47","volume":"vol. 20","author":"Loeza-Uribe","year":"2024"},{"issue":"11","key":"10.1016\/j.jaut.2025.103425_bib59","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jamadermatol.2021.3344","article-title":"UBA1 variations in neutrophilic dermatosis skin lesions of patients with VEXAS syndrome","volume":"157","author":"Zakine","year":"2021","journal-title":"JAMA Dermatol."},{"issue":"5","key":"10.1016\/j.jaut.2025.103425_bib60","doi-asserted-by":"crossref","first-page":"E117","DOI":"10.1093\/rheumatology\/keab866","article-title":"Successful treatment with azacitidine in VEXAS syndrome with prominent myofasciitis","volume":"61","author":"Cordts","year":"2022","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.jaut.2025.103425_bib61","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard-2023-224460","article-title":"Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences about UBA1 mosaicism","volume":"82","author":"Mascaro","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.jaut.2025.103425_bib62","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s44318-024-00046-z","article-title":"Shared and distinct mechanisms of UBA1 inactivation across different diseases","volume":"43","author":"Collins","year":"2024","journal-title":"The EMBO journal"},{"issue":"5","key":"10.1016\/j.jaut.2025.103425_bib63","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s41375-023-01857-5","article-title":"Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies","volume":"37","author":"Sakuma","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jaut.2025.103425_bib64","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41467-024-44811-4","article-title":"VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation","volume":"15","author":"Kosmider","year":"2024","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.jaut.2025.103425_bib65","article-title":"Targeting enhanced cell death represents a potential therapeutic strategy for VEXAS syndrome","volume":"8","author":"Adachi","year":"2024","journal-title":"Rheumatol Adv Pract"},{"issue":"8","key":"10.1016\/j.jaut.2025.103425_bib66","article-title":"Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS","volume":"4","author":"Wu","year":"2023","journal-title":"Cell Rep. Med"},{"issue":"6","key":"10.1016\/j.jaut.2025.103425_bib67","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/RHU.0000000000001905","article-title":"VEXAS syndrome - a review of pathophysiology, presentation, and prognosis","volume":"29","author":"Koster","year":"2023","journal-title":"J. Clin. Rheumatol."},{"issue":"10","key":"10.1016\/j.jaut.2025.103425_bib68","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.medcli.2022.06.018","article-title":"Paradigm shift in monogenic autoinflammatory diseases and systemic vasculitis: the VEXAS syndrome","volume":"159","author":"Hern\u00e1ndez-Rodr\u00edguez","year":"2022","journal-title":"Med. Clin."},{"issue":"2","key":"10.1016\/j.jaut.2025.103425_bib69","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002255","article-title":"Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients","volume":"8","author":"Khitri","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.jaut.2025.103425_bib70","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/art.42101","article-title":"Successful use of cyclosporin A and interleukin-1 blocker combination therapy in VEXAS syndrome: a single-center case series","volume":"74","author":"Campochiaro","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2025.103425_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.983939","article-title":"Vasculitis associated with VEXAS syndrome: a literature review","volume":"9","author":"Watanabe","year":"2022","journal-title":"Front. Med."},{"issue":"9","key":"10.1016\/j.jaut.2025.103425_bib72","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1038\/s41375-021-01353-8","article-title":"Prevalence of UBA1 mutations in MDS\/CMML patients with systemic inflammatory and auto-immune disease","volume":"35","author":"Zhao","year":"2021","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jaut.2025.103425_bib73","doi-asserted-by":"crossref","first-page":"E402","DOI":"10.1093\/rheumatology\/keab392","article-title":"VEXAS syndrome in a woman","volume":"60","author":"Barba","year":"2021","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.jaut.2025.103425_bib74","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3324\/haematol.2021.280238","article-title":"VEXAS syndrome in a female patient with constitutional 45,X (Turner syndrome)","volume":"107","author":"Stubbins","year":"2022","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jaut.2025.103425_bib75","doi-asserted-by":"crossref","first-page":"E67","DOI":"10.1097\/RLU.0000000000004506","article-title":"Aortitis pet imaging in VEXAS syndrome: a case report","volume":"48","author":"Grambow-Velilla","year":"2023","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.jaut.2025.103425_bib76","doi-asserted-by":"crossref","first-page":"E69","DOI":"10.1093\/rheumatology\/keab782","article-title":"VEXAS syndrome: relapsing polychondritis and myelodysplastic syndrome with associated immunoglobulin A vasculitis","volume":"61","author":"P\u00e0mies","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2025.103425_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.108996","article-title":"Beh\u00e7et\u2019s disease with a somatic UBA1 variant:Expanding spectrum of autoinflammatory phenotypes of VEXAS syndrome","volume":"238","author":"Matsumoto","year":"2022","journal-title":"Clin. Immunol."},{"issue":"6","key":"10.1016\/j.jaut.2025.103425_bib78","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaad.2022.01.042","article-title":"VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) for the dermatologist","volume":"89","author":"Sterling","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.jaut.2025.103425_bib79","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/03009742.2022.2045791","article-title":"Orbital and periorbital inflammation in VEXAS syndrome","volume":"51","author":"Mart\u00edn-Nares","year":"2022","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103425_bib80","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jdcr.2022.02.022","article-title":"Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome","volume":"23","author":"Goyal","year":"2022","journal-title":"JAAD Case Rep."},{"issue":"3","key":"10.1016\/j.jaut.2025.103425_bib81","article-title":"Adverse reaction to COVID-19 mRNA vaccination in a patient with VEXAS syndrome","volume":"14","author":"Ciprian","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.jaut.2025.103425_bib82","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1002\/art.41775","article-title":"Extensive multiple organ involvement in VEXAS syndrome","volume":"73","author":"Takahashi","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2025.103425_bib83","doi-asserted-by":"crossref","first-page":"E371","DOI":"10.1093\/rheumatology\/keac356","article-title":"Novel genetic mutation in myositis-variant of VEXAS syndrome","volume":"61","author":"Topilow","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2025.103425_bib84","doi-asserted-by":"crossref","first-page":"E356","DOI":"10.1093\/rheumatology\/keab349","article-title":"A Case of polychondritis-onset refractory organizing pneumonia with cytopaenia diagnosed as VEXAS syndrome: the disease course of 7 years","volume":"60","author":"Sakuma","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2025.103425_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107245","article-title":"Pulmonary manifestations in VEXAS syndrome","volume":"213","author":"Casal Moura","year":"2023","journal-title":"Respir. Med."},{"issue":"6","key":"10.1016\/j.jaut.2025.103425_bib86","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00296-022-05266-2","article-title":"Pulmonary manifestations in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome: a systematic review","volume":"43","author":"Kouranloo","year":"2023","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.jaut.2025.103425_bib87","doi-asserted-by":"crossref","first-page":"E271","DOI":"10.1093\/rheumatology\/kead076","article-title":"VEXAS syndrome mimicking lupus-like disease","volume":"62","author":"Valor-M\u00e9ndez","year":"2023","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.jaut.2025.103425_bib88","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s11739-023-03193-z","article-title":"VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases","volume":"18","author":"Vitale","year":"2023","journal-title":"Intern Emerg Med"},{"issue":"3","key":"10.1016\/j.jaut.2025.103425_bib89","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/25785826.2018.1531188","article-title":"Clinical significance of myositis-specific autoantibodies","volume":"41","author":"Nakashima","year":"2018","journal-title":"Immunol Med"},{"issue":"12","key":"10.1016\/j.jaut.2025.103425_bib90","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.50251","article-title":"Nonischemic cardiac manifestations in VEXAS syndrome","volume":"7","author":"Robert","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"6","key":"10.1016\/j.jaut.2025.103425_bib91","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.kint.2022.03.012","article-title":"Acute tubulointerstitial nephritis revealing VEXAS syndrome","volume":"101","author":"Ronsin","year":"2022","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.jaut.2025.103425_bib92","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ekir.2024.10.026","article-title":"A clinicopathological description of kidney features in VEXAS syndrome","volume":"10","author":"Mathurin","year":"2025","journal-title":"Kidney Int Rep."},{"issue":"4","key":"10.1016\/j.jaut.2025.103425_bib93","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/rheumatology\/keae465","article-title":"Acute kidney injury, an underrecognized feature of VEXAS syndrome","volume":"64","author":"Kalantari","year":"2025","journal-title":"Rheumatology"},{"issue":"10S","key":"10.1016\/j.jaut.2025.103425_bib94","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2024xhm0nymz","article-title":"A clinicopathological description of kidney features in VEXAS syndrome: TH-PO067","volume":"35","author":"Mathurin","year":"2024","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jaut.2025.103425_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/frhem.2024.1480436","article-title":"Case report: VEXAS syndrome and literature review","volume":"3","author":"Jones","year":"2024","journal-title":"Front Hematol."},{"issue":"1","key":"10.1016\/j.jaut.2025.103425_bib96","article-title":"Clinical manifestations in vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: a narrative review","volume":"16","author":"Padureanu","year":"2024","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.jaut.2025.103425_bib97","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000661","article-title":"Azacytidine treatment for VEXAS syndrome","volume":"5","author":"Raaijmakers","year":"2021","journal-title":"HemaSphere"},{"issue":"9","key":"10.1016\/j.jaut.2025.103425_bib98","doi-asserted-by":"crossref","first-page":"E321","DOI":"10.1093\/rheumatology\/keab225","article-title":"VEXAS syndrome: still expanding the clinical phenotype","volume":"60","author":"Oganesyan","year":"2021","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.jaut.2025.103425_bib99","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/bjh.17930","article-title":"Towards treatments for VEXAS","volume":"196","author":"Patel","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.jaut.2025.103425_bib100","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.seminhematol.2021.09.001","article-title":"Toward a pathophysiology inspired treatment of VEXAS syndrome","volume":"58","author":"Heiblig","year":"2021","journal-title":"Semin Hematol."},{"issue":"1\u20132","key":"10.1016\/j.jaut.2025.103425_bib101","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s44228-022-00002-w","article-title":"Clinical, morphological and clonal progression of VEXAS syndrome in the context of myelodysplasia treated with azacytidine","volume":"4","author":"Manzoni","year":"2022","journal-title":"Clin Hematol Int."},{"key":"10.1016\/j.jaut.2025.103425_bib102","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/j.seminhematol.2021.10.005","article-title":"VEXAS syndrome: an inflammatory and hematologic disease","volume":"58","author":"Patel","year":"2021","journal-title":"Semin. Hematol."},{"issue":"2","key":"10.1016\/j.jaut.2025.103425_bib103","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/bloodadvances.2021005243","article-title":"A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm","volume":"6","author":"Li","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaut.2025.103425_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.800149","article-title":"Case report: genetic double strike: VEXAS and TET2-positive myelodysplastic syndrome in a patient with long-standing refractory autoinflammatory disease","volume":"12","author":"L\u00f6tscher","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.jaut.2025.103425_bib105","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1053\/j.seminhematol.2021.10.006","article-title":"Thrombotic manifestations of VEXAS syndrome","volume":"58","author":"Groarke","year":"2021","journal-title":"Semin. Hematol."},{"issue":"7","key":"10.1016\/j.jaut.2025.103425_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12071590","article-title":"VEXAS syndrome: a novelty in MDS landscape","volume":"12","author":"Templ\u00e9","year":"2022","journal-title":"Diagnostics"},{"issue":"4","key":"10.1016\/j.jaut.2025.103425_bib107","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s11239-021-02608-y","article-title":"Thrombosis in VEXAS syndrome","volume":"53","author":"Oo","year":"2022","journal-title":"J. Thromb. Thrombolysis"},{"issue":"3","key":"10.1016\/j.jaut.2025.103425_bib108","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1182\/bloodadvances.2021004749","article-title":"Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience","volume":"6","author":"Diarra","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jaut.2025.103425_bib109","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41409-021-01544-y","article-title":"Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report","volume":"57","author":"Loschi","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.jaut.2025.103425_bib110","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1111\/bjh.18424","article-title":"Case report: up-front allogeneic stem cell transplantation in a patient with the VEXAS syndrome","volume":"199","author":"van Leeuwen-Kerkhoff","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jaut.2025.103425_bib111","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1038\/s41375-022-01698-8","article-title":"A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune\/inflammatory disorders and VEXAS syndrome associated with MDS and CMML","volume":"36","author":"Mekinian","year":"2022","journal-title":"Leukemia."},{"issue":"11","key":"10.1016\/j.jaut.2025.103425_bib112","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1093\/rheumatology\/kead240","article-title":"How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies","volume":"62","author":"Boyadzhieva","year":"2023","journal-title":"Rheumatol"},{"issue":"3","key":"10.1016\/j.jaut.2025.103425_bib113","doi-asserted-by":"crossref","DOI":"10.1111\/exd.15050","article-title":"VEXAS syndrome: a review of cutaneous findings and treatments in an emerging autoinflammatory disease","volume":"33","author":"Saad","year":"2024","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.jaut.2025.103425_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2023.105531","article-title":"VEXAS syndrome: expanding the clinical and molecular spectrum","volume":"90","author":"Robert","year":"2023","journal-title":"Jt. Bone Spine"},{"key":"10.1016\/j.jaut.2025.103425_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.901063","article-title":"Case report: tocilizumab treatment for VEXAS syndrome with relapsing polychondritis: a single-center, 1-year longitudinal observational study in Japan","volume":"13","author":"Kunishita","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.jaut.2025.103425_bib116","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/art.41992","article-title":"VEXAS syndrome: a case series from a single-center cohort of Italian patients with vasculitis","volume":"74","author":"Muratore","year":"2022","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"10.1016\/j.jaut.2025.103425_bib117","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00403-022-02340-4","article-title":"VEXAS syndrome in dermatology","volume":"315","author":"Afsahi","year":"2023","journal-title":"Arch. Dermatol. Res."},{"issue":"4","key":"10.1016\/j.jaut.2025.103425_bib118","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/ajd.13932","article-title":"VEXAS syndrome: a dermatological perspective","volume":"63","author":"Nguyen","year":"2022","journal-title":"Australas. J. Dermatol."},{"issue":"11","key":"10.1016\/j.jaut.2025.103425_bib119","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1007\/s10067-022-06338-1","article-title":"Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS syndrome) with prominent supraglottic larynx involvement: a case-based review","volume":"41","author":"Guerrero-Berm\u00fadez","year":"2022","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103425_bib120","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(21)01430-6","article-title":"Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: fevers, myalgia, arthralgia, auricular chondritis, and erythema nodosum","volume":"398","author":"Dehghan","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jaut.2025.103425_bib121","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/art.42257","article-title":"Clinical images: VEXAS syndrome presenting as treatment-refractory polyarteritis nodosa","volume":"74","author":"Itagane","year":"2022","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1016\/j.jaut.2025.103425_bib122","doi-asserted-by":"crossref","first-page":"170","DOI":"10.5582\/irdr.2023.01020","article-title":"VEXAS syndrome: current clinical, diagnostic and treatment approaches","volume":"12","author":"Kobak","year":"2023","journal-title":"Intractable Rare Dis Res"},{"key":"10.1016\/j.jaut.2025.103425_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1046820","article-title":"A case of VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) with decreased oxidative stress levels after oral prednisone and tocilizumab treatment","volume":"9","author":"Tozaki","year":"2022","journal-title":"Front. Med."},{"issue":"7","key":"10.1016\/j.jaut.2025.103425_bib124","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1007\/s10875-021-01070-y","article-title":"A case of VEXAS syndrome complicated by hemophagocytic lymphohistiocytosis","volume":"41","author":"Grey","year":"2021","journal-title":"J Clin Immunol."},{"issue":"7","key":"10.1016\/j.jaut.2025.103425_bib125","doi-asserted-by":"crossref","first-page":"E174","DOI":"10.1093\/rheumatology\/keac054","article-title":"VEXAS syndrome: favourable clinical and partial haematological responses to subcutaneous abatacept therapy with 30-month follow-up","volume":"61","author":"Pathmanathan","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2025.103425_bib126","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jdcr.2021.06.010","article-title":"Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome\u2014clinical presentation of a newly described somatic, autoinflammatory syndrome","volume":"14","author":"Alhomida","year":"2021","journal-title":"JAAD Case Rep."},{"issue":"2","key":"10.1016\/j.jaut.2025.103425_bib127","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/rheumatology\/kead697","article-title":"Treatment experiences with focus on IL-6R inhibition in patients with VEXAS syndrome and a case of remission with azacytidine treatment","volume":"64","author":"Johansen","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2025.103425_bib128","first-page":"734","volume":"vol. 51","author":"Williams","year":"2024"},{"key":"10.1016\/j.jaut.2025.103425_bib129","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.678927","article-title":"Case report: VEXAS syndrome: from mild symptoms to life-threatening macrophage activation syndrome","volume":"12","author":"Staels","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.jaut.2025.103425_bib130","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jaci.2023.02.017","article-title":"Autoimmune manifestations in VEXAS: opportunities for integration and pitfalls to interpretation","volume":"151","author":"Bruno","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.jaut.2025.103425_bib131","doi-asserted-by":"crossref","first-page":"94","DOI":"10.23822\/EurAnnACI.1764-1489.30","article-title":"Successful rapid subcutaneous desensitization to anakinra in a case with a severe immediate-type hypersensitivity reaction","volume":"50","author":"Yilmaz","year":"2018","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.jaut.2025.103425_bib132","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/15353702231165030","article-title":"JAK inhibitors for the treatment of VEXAS syndrome","volume":"248","author":"Bindoli","year":"2023","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.jaut.2025.103425_bib133","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1111\/1756-185X.14785","article-title":"Tofacitinib as a biologic response modifier in VEXAS syndrome: a case series","volume":"26","author":"Salehi","year":"2023","journal-title":"Int. J. Rheum. Dis."},{"issue":"Supplement 1","key":"10.1016\/j.jaut.2025.103425_bib134","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1182\/blood-2021-150394","article-title":"Clinical efficacy of JAK inhibitors in patients with vexas syndrome: a multicenter retrospective study","volume":"138","author":"Heiblig","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2025.103425_bib135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2023\/6551544","article-title":"VEXAS syndrome in a patient with myeloproliferative neoplasia","volume":"2023","author":"Austestad","year":"2023","journal-title":"Case Rep Hematol."},{"issue":"22","key":"10.1016\/j.jaut.2025.103425_bib136","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13226970","article-title":"VEXAS syndrome: a comprehensive review of current therapeutic strategies and emerging treatments","volume":"13","author":"Alqatari","year":"2024","journal-title":"J. Clin. Med."},{"issue":"12","key":"10.1016\/j.jaut.2025.103425_bib137","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.3324\/haematol.2021.279418","article-title":"Dominance of an UBA1 mutant clone over a CALR mutant clone: from essential thrombocytemia to VEXAS","volume":"106","author":"Hage-Sleiman","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jaut.2025.103425_bib138","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","article-title":"Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial","volume":"403","author":"Cope","year":"2024","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.jaut.2025.103425_bib139","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.2165\/11202840-000000000-00000","article-title":"Azacitidine: a review of its use in higher-risk myelodysplastic syndromes acute myeloid leukaemia","volume":"69","author":"Keating","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.jaut.2025.103425_bib140","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.leukres.2016.02.005","article-title":"Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"43","author":"Fraison","year":"2016","journal-title":"Leuk. Res."},{"issue":"10","key":"10.1016\/j.jaut.2025.103425_bib141","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.3324\/haematol.2024.285519","article-title":"De-escalation of corticosteroids and clonal remission in UBA1 mutation-driven VEXAS syndrome with 5-azacytidine","volume":"109","author":"Trikha","year":"2024","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.jaut.2025.103425_bib142","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.129","article-title":"Long-term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome","volume":"8","author":"Aalbers","year":"2024","journal-title":"HemaSphere"},{"issue":"6","key":"10.1016\/j.jaut.2025.103425_bib143","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s12185-023-03532-y","article-title":"Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome","volume":"117","author":"Kataoka","year":"2023","journal-title":"Int. J. Hematol."},{"issue":"3","key":"10.1016\/j.jaut.2025.103425_bib144","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00277-023-05611-w","article-title":"VEXAS syndrome: complete molecular remission after hypomethylating therapy","volume":"103","author":"Sockel","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.jaut.2025.103425_bib145","first-page":"E28","volume":"vol. 98","author":"Mangaonkar","year":"2023"},{"issue":"6","key":"10.1016\/j.jaut.2025.103425_bib146","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1182\/bloodadvances.2023012478","article-title":"Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT","volume":"8","author":"Gurnari","year":"2024","journal-title":"Blood Adv"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125000708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125000708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T11:07:35Z","timestamp":1749726455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841125000708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":146,"alternative-id":["S0896841125000708"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103425","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"VEXAS syndrome: A newly identified X-Linked hematoinflammatory disorder \u2013 A comprehensive overview of its genetic, molecular, inflammatory, and clinical landscape","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103425","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103425"}}